Invasive lobular carcinoma of the breast: the increasing importance of this special subtype
AE McCart Reed, L Kalinowski, PT Simpson… - Breast Cancer …, 2021 - Springer
Invasive lobular carcinoma (ILC) is the most common of the breast cancer special types,
accounting for up to 15% of all breast cancer cases. ILCs are noted for their lack of E …
accounting for up to 15% of all breast cancer cases. ILCs are noted for their lack of E …
Invasive lobular carcinoma: an understudied emergent subtype of breast cancer
JA Mouabbi, A Hassan, B Lim, GN Hortobagyi… - Breast cancer research …, 2022 - Springer
Invasive lobular carcinoma (ILC) is the second most common histologic subtype of breast
cancer after invasive ductal carcinoma (IDC), accounting for 10–15% of all breast cancer …
cancer after invasive ductal carcinoma (IDC), accounting for 10–15% of all breast cancer …
Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity
Activating mutations in HER2 (ERBB2) drive the growth of a subset of breast and other
cancers and tend to co-occur with HER3 (ERBB3) missense mutations. The HER2 tyrosine …
cancers and tend to co-occur with HER3 (ERBB3) missense mutations. The HER2 tyrosine …
The phase II MutHER study of neratinib alone and in combination with fulvestrant in HER2-mutated, non-amplified metastatic breast cancer
CX Ma, J Luo, RA Freedman, TJ Pluard, JR Nangia… - Clinical Cancer …, 2022 - AACR
Abstract Purpose: HER2 mutations (HER2mut) induce endocrine resistance in estrogen
receptor–positive (ER+) breast cancer. Patients and Methods: In this single-arm multi-cohort …
receptor–positive (ER+) breast cancer. Patients and Methods: In this single-arm multi-cohort …
Clinicopathological features and outcomes comparing patients with invasive ductal and lobular breast cancer
Background There is increasing interest in better understanding the biology and clinical
presentation of invasive lobular cancer (ILC), which is the most common special histological …
presentation of invasive lobular cancer (ILC), which is the most common special histological …
Lobular breast cancer: histomorphology and different concepts of a special spectrum of tumors
Simple Summary Invasive lobular breast cancer (ILC) is a special type of breast cancer (BC)
that was first described in 1941. The diagnosis of ILC is made by microscopy of tumor …
that was first described in 1941. The diagnosis of ILC is made by microscopy of tumor …
Somatic Mutations in HER2 and Implications for Current Treatment Paradigms in HER2‐Positive Breast Cancer
M Gaibar, L Beltrán, A Romero-Lorca… - Journal of …, 2020 - Wiley Online Library
In one of every four or five cases of breast cancer, the human epidermal growth factor
receptor‐2 (HER2) gene is overexpressed. These carcinomas are known as HER2‐positive …
receptor‐2 (HER2) gene is overexpressed. These carcinomas are known as HER2‐positive …
[HTML][HTML] Neratinib+ fulvestrant+ trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the …
K Jhaveri, LD Eli, H Wildiers, SA Hurvitz… - Annals of …, 2023 - Elsevier
Background HER2 mutations are targetable alterations in patients with hormone receptor-
positive (HR+) metastatic breast cancer (MBC). In the SUMMIT basket study, patients with …
positive (HR+) metastatic breast cancer (MBC). In the SUMMIT basket study, patients with …
A comprehensive review of protein misfolding disorders, underlying mechanism, clinical diagnosis, and therapeutic strategies
Introduction The most prevalent biological macromolecules in living systems are proteins,
the building block of life, extremely dynamic in structure and functions. Due to several …
the building block of life, extremely dynamic in structure and functions. Due to several …
Acquired Secondary HER2 Mutations Enhance HER2/MAPK Signaling and Promote Resistance to HER2 Kinase Inhibition in Breast Cancer
A Marín, AA Mamun, H Patel, H Akamatsu, D Ye… - Cancer research, 2023 - AACR
HER2 mutations drive the growth of a subset of breast cancers and are targeted with HER2
tyrosine kinase inhibitors (TKI) such as neratinib. However, acquired resistance is common …
tyrosine kinase inhibitors (TKI) such as neratinib. However, acquired resistance is common …